Research Paper Volume 12, Issue 12 pp 11717—11731

Resveratrol inhibits the malignant progression of hepatocellular carcinoma via MARCH1-induced regulation of PTEN/AKT signaling

Figure 1. Resveratrol inhibits HCC cell viability. (A) Representative images of HepG2 and Hep3B cells treated with different concentrations of resveratrol for 48 h. (B) The cytotoxicity of HepG2 and Hep3B cells treated with resveratrol was estimated by CCK-8 assays. HepG2 and Hep3B cells were treated with different concentrations of resveratrol for 48 h. The absorbance at 450 nm is detected. (C) Western blot analysis showed that MARCH1 expression decreased after resveratrol treated for 48 h in both HepG2 and Hep3B cells. GAPDH was also detected as the loading control. (D) HepG2 cells were treated with the indicated dose of resveratrol for 24h and then analyzed the transcription level of MARCH1. MARCH1 mRNA levels were normalized to GAPDH. (E) HepG2 cells were pretreated with 0.25μM MG132 for 24h, then analyzed the expression of MARCH1. (F, G) HepG2 cells were treated with the indicated dose of empty vectors and overexpression plasmids for 48h, then incubation with resveratrol for 24h. (H) The expression of MARCH1 were detected. All values represent the mean ± SD. **P < 0.01; *P < 0.05.